Yamashita J, Shirakusa T, Fujino N, Kiyama T, Kinuwaki E, Ogawa M
FUKUOKA UNIV,SCH MED,DEPT SURG 2,NANAKUMA 7-45-1,FUKUOKA 81401,JAPAN. KUMAMOTO CITY HOSP,DEPT PULMONOL,KUMAMOTO 862,JAPAN. KUMAMOTO UNIV,SCH MED,DEPT SURG 2,KUMAMOTO 860,JAPAN.
Oncol Rep. 1995 Mar;2(2):215-9. doi: 10.3892/or.2.2.215.
It has been suggested that a proportion of patients with cancer have an ongoing acute phase response indicated by a raised C-reactive protein (CRP). To examine whether an acute phase protein response is associated with circulating interleukin-6 (IL-6) concentrations in patients with lung cancer, we measured serum levels of CRP and interleukin (IL)-6 in 176 patients with lung cancer and 48 patients with other pulmonary diseases (28 diffuse pulmonary infiltrates, 15 benign lung tumors, and 5 bronchial asthmas). Serum CRP was detectable (greater-than-or-equal-to 2.5 mg/liter) in 57.4% of patients with lung cancer, 78.6% of patients with diffuse pulmonary infiltrates, 46.7% of patients with benign lung tumors, and 40.0% of patients with bronchial asthma. Serum IL-6 was detectable in all patients by a highly sensitive enzyme-immunoassay, the concentration ranging from 0.126 to 35.115 pg/ml. Although there was no significant difference in serum IL-6 levels among the histologic types of lung cancer, the IL-6 concentration was significantly higher in patients with advanced cancers than in those with early ones. Correlation analyses showed that there was no significant relationship between the CRP and IL-6 concentrations in the 176 patients with lung cancer (r=0.212, P=0.1243), while a highly significant correlation between both levels was observed in the 28 patients with diffuse pulmonary infiltrates (r=0.783, P=0.0005). These results indicate that the serum IL-6 level in patients with lung cancer is closely associated with the disease stage, but that a raised CRP concentration occurs independently of circulating IL-6 concentrations in patients with lung cancer.
有人提出，一部分癌症患者存在持续的急性期反应，表现为C反应蛋白（CRP）升高。为了研究急性期蛋白反应是否与肺癌患者循环白细胞介素-6（IL-6）浓度相关，我们检测了176例肺癌患者和48例其他肺部疾病患者（28例弥漫性肺浸润、15例良性肺肿瘤和5例支气管哮喘）的血清CRP和白细胞介素（IL）-6水平。57.4%的肺癌患者、78.6%的弥漫性肺浸润患者、46.7%的良性肺肿瘤患者和40.0%的支气管哮喘患者血清CRP可检测到（大于或等于2.5毫克/升）。通过高灵敏度酶免疫测定法，所有患者血清IL-6均可检测到，浓度范围为0.126至35.115皮克/毫升。虽然肺癌组织学类型之间血清IL-6水平无显著差异，但晚期癌症患者的IL-6浓度显著高于早期患者。相关性分析表明，176例肺癌患者中CRP和IL-6浓度之间无显著关系（r = 0.212，P = 0.1243），而28例弥漫性肺浸润患者中两者水平呈高度显著相关（r = 0.783，P = 0.0005）。这些结果表明，肺癌患者血清IL-6水平与疾病分期密切相关，但肺癌患者CRP浓度升高独立于循环IL-6浓度。
